Bibliography
- Hebert LE , ScherrPA, BieniasJL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol.60,1119–1122 (2003).
- Godbolt AK , CipolottiL, WattH, FoxNC, JanssenJC, RossorMN: The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort.Arch. Neurol.61,1743–1748 (2004).
- Skovronsky DM , Lee VM-Y, Trojanowski JQ: Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. Mech. Dis.1,151–170 (2006).
- Gandy S : The role of cerebral amyloid β accumulation in common forms of Alzheimer disease.J. Clin. Invest.115,1121–1129 (2005).
- Small GW , RabinsPV, BarryPP et al.: Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer‘s Association, and the American Aeriatrics Society.JAMA278,1363–1371 (1997).
- Desai AK , GrossbergGT: Diagnosis and treatment of Alzheimer‘s disease.Neurology64,S34–S39 (2005).
- Frank RA , GalaskoD, HampelH et al.: Biological markers for therapeutic trials in Alzheimer‘s disease: Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer‘s disease. Neurobiol. Aging24,521–536 (2003).
- Mueller SG , WeinerMW, ThalL et al.: Ways toward an early diagnosis in Alzheimer‘s disease: The Alzheimer‘s Disease Neuroimaging Initiative (ADNI). Alz. Dementia1,55–66 (2005).
- Thal LJ , KantarciK, ReimanEM et al.: The role of biomarkers in clinical trials for Alzheimer disease. Alz. Dis. Assoc. Disord.20,6–15 (2006).
- Henley S , BatesG, TabriziS: Biomarkers for neurodegenerative diseases.Curr. Opin. Neurol.18,698–705 (2005).
- Iqbal K , FloryM, KhatoonS et al.: Subgroups of Alzheimer‘s disease based on cerebrospinal fluid molecular markers. Ann. Neurol.58,748–757 (2005).
- Doody RS , MassmanP, DunnJK: A method for estimating progression rates in Alzheimer disease.Arch. Neurol.58,449–454 (2001).
- Klunk WE , EnglerH, NordbergA et al.: Imaging brain amyloid in Alzheimer‘s disease with Pittsburgh Compound-B. Ann. Neurol.55,306–319 (2004).
- Fagan AM , MintunMA, MachRH et al.: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol.59,512–519 (2006).
- Hardy J , SelkoeDJ: The amyloid hypothesis of Alzheimer‘s disease: progress and problems on the road to therapeutics.Science297,353–356 (2002).
- Gong Y , ChangL, ViolaKL et al.: Alzheimer‘s disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA100,10417–10422 (2003).
- Lesne S , KohMT, KotilinekL et al.: A amyloid-β protein assembly in the brain impairs memory. Nature440,352–357 (2006).
- Mayeux R , HonigLS, Tang M-X et al.: Plasma Aβ40 and Aβ42 and Alzheimer‘s disease: relation to age, mortality, and risk. Neurology61,1185–1190 (2003).
- Irizarry MC : Biomarkers of Alzheimer disease in plasma.NeuroRx1,226–234 (2004).
- Hühmer AF , BiringerRG, AmatoH, Fonteh AN, Harrington MG: Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. Dis. Markers22,211–234 (2006).
- Andreasen N , BlennowK: CSF biomarkers for mild cognitive impairment and early Alzheimer‘s disease.Clin. Neurol. Neurosurg.107,165–173 (2005).
- Chamberlain M : Neoplastic meningitis: a guide to diagnosis and treatment.Curr. Opin. Neurol.13,641–648 (2000).
- Blennow K , WallinA, HagerO: Low frequency of post-lumbar puncture headache in demented patients.Acta Neurol. Scand.88,221–223 (1993).
- Peskind E , RiekseR, QuinnJ et al.: Safety and acceptability of the research lumbar puncture. Alz. Dis. Assoc. Disord.19,220–225 (2005).
- Blennow K : CSF biomarkers for Alzheimer‘s disease: use in early diagnosis and evaluation of drug treatment.Exp. Rev. Mol. Diag.5,661–672 (2005).
- Schmidt O , SchulenborgT, MeyerHE, MarcusK, HamacherM: How proteomics reveals potential biomarkers in brain diseases.Exp. Rev. Proteomics2,901–913 (2005).
- Puchades M , HanssonSF, NilssonCL, AndreasenN, BlennowK, DavidssonP: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer‘s disease.Mol. Brain Res.118,140–146 (2003).
- Hu Y , MaloneJP, FaganAM, Townsend RR, Holtzman DM: Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol. Cell. Proteomics4,2000–2009 (2005).
- You J , GelfanovaV, KniermanM, WitzmannF, WangM, HaleJ: The impact of blood contamination on the proteome of cerebrospinal fluid.Proteomics5,290–296 (2005).
- Xiao Z , PrietoD, ConradsTP, VeenstraTD, IssaqHJ: Proteomic patterns: their potential for disease diagnosis.Mol. Cell. Endocrind.230,95–106 (2005).
- Petricoin EF , ArdekaniAM, HittBA et al.: Use of proteomic patterns in serum to identify ovarian cancer.Lancet359,572–577 (2002).
- Petricoin EF , LiottaLA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer.Curr. Opin. Biotechnol.15,24–30 (2004).
- Baggerly KA , MorrisJS, CoombesKR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments.Bioinformatics20,777–785 (2004).
- Carrette O , DemalteI, ScherlA et al.: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer‘s disease. Proteomics3,1486–1494 (2003).
- Lewczuk P , EsselmannH, GroemerTW et al.: Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer‘s disease. Biol. Psych.55,524–530 (2004).
- Zhang J , GoodlettDR, QuinnJF et al.: Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alz. Dis.7,125–133 (2005).
- Wang W , ZhouH, LinH et al.: Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem.75,4818–4826 (2003).
- Roy S , AnderleM, LinH, BeckerC: Differential expression profilng of serum proteins and metabolites for biomarker discovery.Intl J. Mass Spect.238,163–171 (2004).
- Galasko D : Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement?Arch. Neurol.60,1195–1196 (2003).
- Maddalena A , PapassotiropoulosA, Muller-TillmannsB et al.: Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide 42. Arch. Neurol.60,1202–1206 (2003).
- Sunderland T , LinkerG, MirzaN et al.: Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.JAMA289,2094–2103 (2003).
- Blennow K : Cerebrospinal fluid protein biomarkers for Alzheimer‘s disease.NeuroRx1,213–225 (2004).
- Rowan MJ , KlyubinI, WangQ, AnwylR: Synaptic plasticity disruption by amyloid-β protein: modulation by potential Alzheimer‘s disease modifying therapies.Biochem. Soc. Trans.33,563–567.
- Hansson O , ZetterbergH, BuchhaveP, LondosE, BlennowK, MinthonL: Association between CSF biomarkers and incipient Alzheimer‘s disease in patients with mild cognitive impairment: a follow-up study.Lancet Neurol.5,228–234 (2006).
- Olsson A , VandersticheleH, AndreasenN et al.: Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem.51,336–345 (2005).
- Praticò D , ClarkCM, LeeVM, Trojanowski JQ, Rokach J, FitzGerald GA: Increased 8,12-iso-iPF2α-VI in Alzheimer‘s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol.48,809–812 (2000).
- Praticò D , ClarkCM, LiunF, Lee VY-M, Trojanowski JQ: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol.59,972–976 (2002).
- de Leon MJ , DeSantiS, ZinkowskiR et al.: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging27,394–401 (2006).
- Han X , HoltzmanD, McKeelD Jr, Kelley J, Morris J: Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer‘s disease: potential role in disease pathogenesis. J. Neurochem.82,809–818 (2002).